Phase 3 Readout

NKTR: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Effica

Name: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Effica
Start: 2028-12-01
End: 2028-12-01

December 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2028
Company: NEKTAR THERAPEUTICS (NKTR)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Effica

December 1, 2028

NKTR overview →

Company: NEKTAR THERAPEUTICS (NKTR)
Indication: Moderate-to-Severe Atopic Dermatitis